A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome

Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects such as atrial fibrillation, bleedi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozturk, Erman, Erdogan Ozunal, Isıl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Istanbul Medeniyet University 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226401/
https://www.ncbi.nlm.nih.gov/pubmed/34239769
http://dx.doi.org/10.5222/MMJ.2021.56424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226401/
https://www.ncbi.nlm.nih.gov/pubmed/34239769
http://dx.doi.org/10.5222/MMJ.2021.56424

Ejemplares similares